Stay updated with breaking news from Sandoz Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Brand pharma companies invest valuable resources, time, and money in moving drugs from development to FDA approval. The new drug approval may also enjoy some type of FDA exclusivity.
Stocks to watch: Shares of firms like PB Fintech, HPCL, Godrej Consumer, LTIMindtree, Lupin, Gujarat Gas, and others will be in focus on Tuesday's trade.
Mumbai, Naples, May 06, 2024: Global pharma major Lupin Limited today announced that it has received approval from the United States Food and Drug Administration for its Abbreviated...
Case Name: Genentech, Inc. v. Sandoz, Inc., Civ No. 23-4085 (JXN)(LDW), 2024 WL 939692 (D.N.J. Mar. 5, 2024) (Wettre, M.J.) - Drug Product and Patent(s)-in-Suit: Esbriet® (pirfenidone);...
More than $160 million separate generic-drug maker Sandoz Inc. and biopharmaceutical firm United Therapeutics Corp. in their estimates of damages suffered by Sandoz when the other company effectively blocked the sale of Sandoz's generic version of a hypertension medication, according to opening statements Monday during a bench trial in New Jersey federal court.